Volume 29, Number 9—September 2023
Dispatch
Laboratory Diagnosis of Mpox, Central African Republic, 2016–2022
Table 1
Specimen type | MPXV (G2RG) |
MPXV (C3L) |
VZV |
|||||
---|---|---|---|---|---|---|---|---|
Positive | Negative | Positive | Negative | Positive | Negative | |||
Blood | 77/278 (28) | 201/278 (72) | 73/278 (26) | 205/278 (74) | 62/260 (24) | 198/260 (76) | ||
Active lesion | 45/102 (44) | 57/102 (56) | 45/102 (44) | 57/102 (56) | 42/108 (39) | 66/108 (61) | ||
Scab | 36/98 (37) | 62/98 (63) | 37/98 (38) | 61/98 (62) | 38/100 (38) | 62/100 (62) | ||
Oropharyngeal | 3/22 (14) | 19/22 (86) | 2/22 (9) | 20/22 (91) | 6/22 (27) | 16/22 (73) |
*Data are no. positive/no. tested (%). C3L, clade I–specific primer; G2RG, generic primer; MPXV, monkeypox virus; VZV, varicella–zoster virus.
1These first authors contributed equally to this article.
2These senior authors contributed equally to this article.
Page created: July 05, 2023
Page updated: August 20, 2023
Page reviewed: August 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.